By Alice Goodman December 10, Advertisement. Recent studies have more clearly defined the role of pertuzumab Perjeta and neratinib Nerlynx. A question currently on the table is the optimal duration of trastuzumab. A recent study Persephone demonstrated that 6 months of trastuzumab is noninferior to 1 year. This is a more attractive option because of reduced potential for side effects, lower cost, and patient convenience, but experts agree that shorter treatment duration has not been definitively established.
Management of HER2-Positive Breast Cancer: Business as Usual?
HER2-positive breast cancer: Causes, prevalence, and diagnosis
The past 30 years have seen many advances in the treatment of breast cancer. This protein is an important part of the pathway for cell growth and survival. A targeted therapy is a drug designed to attack a particular molecular agent or pathway involved in the development of cancer. Unlike chemotherapy drugs, targeted therapies kill cancer cells with little harm to healthy cells. A targeted therapy will only work on cancers that have the specific marker it was designed to attack. Different anti-HER2 drugs work in different ways.
HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 HER2 , which promotes the growth of cancer cells. In about 1 of every 5 breast cancers, the cancer cells have a gene mutation that makes an excess of the HER2 protein. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer.